Q-omics provides the consensus-scored IMPDH1P10 profile across patient tissues and cancer cell-line models. IMPDH1P10 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IMPDH1P10 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, IMPDH1P10 RNA expression shows 16,452 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where IMPDH1P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMPDH1P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMPDH1P10 survival associations across molecular data types. IMPDH1P10 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMPDH1P10 RNA expression–survival associations across cancer types. High IMPDH1P10 expression shows unfavorable associations in LGG and PRAD, but favorable associations in BLCA, ESCA, HNSC and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for IMPDH1P10 RNA expression.
This table summarizes IMPDH1P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IMPDH1P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMPDH1P10 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, STAD, CHOL and COAD. The KIRC box plot shows higher IMPDH1P10 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p < 0.001).
This table shows molecular features associated with IMPDH1P10 in patient tissues and cancer cell lines. In patient samples, IMPDH1P10 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
